Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyHarmaline
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Harmaline
- Accession Number
- DB13875
- Type
- Small Molecule
- Groups
- Experimental
- Description
- Not Available
- Structure
- Synonyms
- Not Available
- Product Ingredients
Ingredient UNII CAS InChI Key Harmaline hydrochloride 64056X913V 363-11-1 PULNGKOFHCQQQA-UHFFFAOYSA-N Harmaline hydrochloride dihydrate 5B4DGH2M9R 6027-98-1 LCEKUHFBUFUSSY-UHFFFAOYSA-N - Categories
- Agents that produce hypertension
- Agents that reduce seizure threshold
- Alkaloids
- Antidepressive Agents
- Carbolines
- Central Nervous System Agents
- Central Nervous System Depressants
- Central Nervous System Stimulants
- Enzyme Inhibitors
- Harmala Alkaloids
- Heterocyclic Compounds, Fused-Ring
- Indole Alkaloids
- Indoles
- Monoamine Oxidase Inhibitors
- Pyridines
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- UNII
- CN58I4TOET
- CAS number
- 304-21-2
- Weight
- Average: 214.2631
Monoisotopic: 214.11061308 - Chemical Formula
- C13H14N2O
- InChI Key
- RERZNCLIYCABFS-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H14N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-4,7,15H,5-6H2,1-2H3
- IUPAC Name
- 7-methoxy-1-methyl-3H,4H,9H-pyrido[3,4-b]indole
- SMILES
- COC1=CC2=C(C=C1)C1=C(N2)C(C)=NCC1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UHistamine N-methyltransferase inhibitorHumans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional Data(R)-warfarin The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with (R)-warfarin. (S)-Warfarin The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with (S)-Warfarin. 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid The risk or severity of hypertension can be increased when 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid is combined with Harmaline. 1-benzylimidazole The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Harmaline. 2,4-thiazolidinedione Harmaline may increase the hypoglycemic activities of 2,4-thiazolidinedione. 2,5-Dimethoxy-4-ethylamphetamine Harmaline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine. 2,5-Dimethoxy-4-ethylthioamphetamine Harmaline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylthioamphetamine. 4-Bromo-2,5-dimethoxyamphetamine Harmaline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine. 4-hydroxycoumarin The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with 4-hydroxycoumarin. 4-Methoxyamphetamine Harmaline may increase the hypertensive activities of 4-Methoxyamphetamine. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0030310
- KEGG Compound
- C06536
- PubChem Compound
- 5280951
- PubChem Substance
- 347829327
- ChemSpider
- 10211258
- BindingDB
- 50029799
- ChEBI
- 28172
- ChEMBL
- CHEMBL340807
- Wikipedia
- Harmaline
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0576 mg/mL ALOGPS logP 2.61 ALOGPS logP 1.67 ChemAxon logS -3.6 ALOGPS pKa (Strongest Acidic) 14.95 ChemAxon pKa (Strongest Basic) 6.46 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 37.38 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 64.15 m3·mol-1 ChemAxon Polarizability 24.2 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-00di-2920000000-44473ef3fbb78c164b21
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as harmala alkaloids. These are compounds with a structure based on harmaline, harmine, harmalol, harman or a derivative of those parents. These parents are beta-carbolines, consisting of a pyrimidine fused to the pyrrole moiety of an indole to form a pyrido[3,4-b]indole.
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- Harmala alkaloids
- Sub Class
- Not Available
- Direct Parent
- Harmala alkaloids
- Alternative Parents
- Beta carbolines / 3-alkylindoles / Anisoles / Alkyl aryl ethers / Pyrroles / Heteroaromatic compounds / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- Harmaline / Harman / Beta-carboline / Pyridoindole / 3-alkylindole / Indole or derivatives / Indole / Anisole / Alkyl aryl ether / Benzenoid show 16 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- harmala alkaloid (CHEBI:28172) / Indole alkaloids (C06536) / an alkaloid (CPD-9939)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Histamine n-methyltransferase activity
- Specific Function
- Inactivates histamine by N-methylation. Plays an important role in degrading histamine and in regulating the airway response to histamine.
- Gene Name
- HNMT
- Uniprot ID
- P50135
- Uniprot Name
- Histamine N-methyltransferase
- Molecular Weight
- 33294.765 Da
References
- Cumming P, Vincent SR: Inhibition of histamine-N-methyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydroacridine (tacrine) and by beta-carbolines. Biochem Pharmacol. 1992 Sep 1;44(5):989-92. [PubMed:1530666]
Drug created on August 02, 2017 13:23 / Updated on December 09, 2019 19:37